The global hepatitis C market size is calculated at USD 8.16 billion in 2025 and is forecasted to reach around USD 10.62 billion by 2034, accelerating at a CAGR of 3% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Hepatitis C Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Hepatitis C Market, by Drug Class
8.1.1. HCV Protease Inhibitors
8.1.1.1. Market Revenue and Forecast
8.1.2. HCV Polymerase Inhibitors
8.1.2.1. Market Revenue and Forecast
8.1.3. HCV NSSA Inhibitors
8.1.3.1. Market Revenue and Forecast
8.1.4. Combination Therapy
8.1.4.1. Market Revenue and Forecast
8.1.5. Interferon and Antiviral
8.1.5.1. Market Revenue and Forecast
8.1.6. Peginterferon alfa 2a
8.1.6.1. Market Revenue and Forecast
8.1.7. Peginterferon alfa 2b
8.1.7.1. Market Revenue and Forecast
8.1.8. Ribavirin
8.1.8.1. Market Revenue and Forecast
8.1.9. Others
8.1.9.1. Market Revenue and Forecast
9.1. Hepatitis C Market, by Distribution Channel
9.1.1. Hospital & Retail Pharmacies
9.1.1.1. Market Revenue and Forecast
9.1.2. Online Pharmacies
9.1.2.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class
10.1.2. Market Revenue and Forecast, by Distribution Channel
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Class
10.1.3.2. Market Revenue and Forecast, by Distribution Channel
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Class
10.1.4.2. Market Revenue and Forecast, by Distribution Channel
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class
10.2.2. Market Revenue and Forecast, by Distribution Channel
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Class
10.2.3.2. Market Revenue and Forecast, by Distribution Channel
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Class
10.2.4.2. Market Revenue and Forecast, by Distribution Channel
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Class
10.2.5.2. Market Revenue and Forecast, by Distribution Channel
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Class
10.2.6.2. Market Revenue and Forecast, by Distribution Channel
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class
10.3.2. Market Revenue and Forecast, by Distribution Channel
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Class
10.3.3.2. Market Revenue and Forecast, by Distribution Channel
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Class
10.3.4.2. Market Revenue and Forecast, by Distribution Channel
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Class
10.3.5.2. Market Revenue and Forecast, by Distribution Channel
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Class
10.3.6.2. Market Revenue and Forecast, by Distribution Channel
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class
10.4.2. Market Revenue and Forecast, by Distribution Channel
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Class
10.4.3.2. Market Revenue and Forecast, by Distribution Channel
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Class
10.4.4.2. Market Revenue and Forecast, by Distribution Channel
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class
10.4.5.2. Market Revenue and Forecast, by Distribution Channel
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Class
10.4.6.2. Market Revenue and Forecast, by Distribution Channel
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class
10.5.2. Market Revenue and Forecast, by Distribution Channel
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Class
10.5.3.2. Market Revenue and Forecast, by Distribution Channel
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Class
10.5.4.2. Market Revenue and Forecast, by Distribution Channel
11.1. Bristol-Myers Squibb Company
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Gilead Sciences, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Abbvie
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Kadmon Holdings Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmon La Roche Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. GlaxoSmithKline
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. J & J
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Lupin Pharmaceuticals, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Merck & Co., Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Teva Pharmaceuticals
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample